hotspot -WSS

hotspot

author：hotspot 2025-09-28 01:16:32 - browse：9

The sign of University of Texas MD Anderson Cancer Center in Houston, Texas in front of the Sheikh Zayed Building — coverage from STAT — Adobe

Early last year, MD Anderson Cancer Center leadership had a problem on their hands: a contentious dispute between one of its most powerful researchers and a junior scientist over authorship, credit, and charges of verbal abuse. High-ranking officials at the cancer center tried — and failed — to resolve the feud, and documents obtained by STAT shed new light on the deep divisions at the heart of this case.

The Texas cancer center outsourced assessing the conflict between early-career nephrologist Jamie Lin and leading oncologist Padmanee Sharma to the law firm Ropes & Gray. The firm investigated the authorship and scientific credit portions of the dispute and concluded that Sharma was likely responsible for a scientific hypothesis at the heart of the feud and should be named as a co-senior author on a key manuscript.

But a separate investigation, commissioned by Lin and conducted by a former official at the federal Office of Research Integrity, tells a somewhat different story. That review looked into plagiarism after Sharma claimed Lin had wrongly omitted the senior researcher as an author from a manuscript built on research to which Sharma contributed. But this second investigation found no evidence of plagiarism between two manuscripts submitted to the journals Cancer Immunology Research and Journal of Clinical Investigation Insight.

Lin provided STAT with copies of an executive summary of the Ropes & Gray investigation as well as the conclusions of the plagiarism investigation. These documents are alluded to in legal filings but have not been previously reported. Lin has filed a lawsuit against Sharma in the Harris County District Court alleging retaliation, harassment, threatening, and intellectual theft by Sharma; she’s also asking for $5 million in damages.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： 3 questions for the future of Biden's cancer moonshot

hotspot

WSS

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Senate panel eyes new effort on drug shortages

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Was Amgen transparent enough on FDA's concern on cancer drug?

3 questions for the future of Biden's cancer moonshot

ASCO Takeaways: Winners, snoozers, and the art of cancer care

Wikipedia

hotspot

leisure time

BioMarin wins approval for gene therapy to treat hemophilia A

Why Charlie Gard's case is so disturbing to Americans

Wildfire smoke exposes gaps in outdoor worker protections

BD to buy Edwards patient monitoring unit for $4.2 billion

Medical leaders decry Supreme Court decision on affirmative action

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

The cancer drug shortage isn’t new — and neither are the solutions

Fight over Supreme Court dialysis ruling puts kidney patients at risk

At least 13 dead in Texas as scorching temps continue

Illumina board agrees to spin off Grail, as divestment plans proceed

leisure time

Why Charlie Gard's case is so disturbing to Americans

Why Charlie Gard's case is so disturbing to Americans

When women are denied an abortion, their children fare worse than peers

FDA rejects Alnylam's heart disease treatment over insufficient data

FDA authorizes Novavax’s updated Covid

Chemotherapy drug shortage eases slightly but still widespread

knowledge

hotspot

focus

focus